Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway

Frontiers in Oncology

Shashanka K. Prasad¹  Sushma Pradeep¹  Chandan Dharmashekar¹  Chandan Shivamallu¹  R Pruthvish²  Asad Syed³  Raghavendra G. Amachawadi⁴  Victor Stupin⁵  Ekaterina Silina⁶  Anisha S. Jain⁷  Ashwini Prasad⁷  Shiva Prasad Kollur⁸  Raghu Ram Achar⁹ 

[1]Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India

[2]Department of Biotechnology, Acharya Institute of Technology, Bengaluru, India

[3]Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia

[4]Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States

[5]Department of Hospital Surgery, N.I. Pirogov Russian National Research Medical University (RNRMU), Moscow, Russia

[6]Department of Human Pathology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

[7]Department of Microbiology, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India

[8]Department of Sciences, Amrita School of Arts and Sciences, Amrita Vishwa Vidyapeetham, Mysuru, India

[9]Division of Biochemistry, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, India

关键词: non-small cell lung cancer;    drug repurposing/repositioning;    MAPK;    targeted therapy;    inhibitors;   

DOI  :  10.3389/fonc.2021.741326

来源: DOAJ

【 摘 要 】

Non-small cell lung cancer (NSCLC) is a prominent subtype of lung carcinoma that accounts for the majority of cancer-related deaths globally, and it is responsible for about 80% to 85% of lung cancers. Mitogen-Activated Protein Kinase (MAPK) signaling pathways are a vital aspect of NSCLC, and have aided in the advancement of therapies for this carcinoma. Targeting the Ras/Raf/MEK/ERK pathway is a promising and alternative method in NSCLC treatment, which is highlighted in this review. The introduction of targeted medicines has revolutionized the treatment of patients with this carcinoma. When combined with current systems biology-driven stratagems, repurposing non-cancer drugs into new therapeutic niches presents a cost-effective and efficient technique with enhancing outcomes for discovering novel pharmacological activity. This article highlights the successful cutting-edge techniques while focusing on NSCLC targeted therapies. The ultimate challenge will be integrating these repurposed drugs into the therapeutic regimen of patients affected with NSCLC to potentially increase lung cancer cure rates.

【 授权许可】

Unknown